Skip to main content
. 2015 Apr 14;7(6):831–847. doi: 10.15252/emmm.201404396

Figure 3.

Figure 3

Screening of epigenetic drugs for upregulation of miRNAs and downregulation of ZEB1
  1. Heat map showing the relative expression levels after drug treatment for 48 h in Panc1. Values measured by qRT–PCR were depicted with the software GENE-E. Only mocetinostat upregulated the miRNAs and downregulated ZEB1.
  2. Relative expression of indicated genes in Panc1 measured by qRT–PCR after treatment with different HDAC inhibitors. Note the downregulation of ZEB1 and upregulation of miR-203, miR-200, and E-cadherin by mocetinostat. n = 3, mean ± SEM; unpaired Student's t-test. For significance, see Supplementary Table S1.
  3. Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.
  4. Chromatin immunoprecipitation analysis validated mocetinostat-induced (1 μM, 48 h) enrichment of the active histone marks H3ac, H4ac, H3K9ac, and H3K4me3 at ZEB1 target gene loci in Panc1. n = 3, mean ± SEM; unpaired Student's t-test.
  5. Mocetinostat treatment reduced expression of the anti-apoptotic miR-203 target survivin and sphere-forming capacity in Panc1 when pre-treated with mocetinostat for 48 h. n = 3, mean ± SEM; Mann–Whitney U-test.
Source data are available online for this figure.
HHS Vulnerability Disclosure